Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Obstetrics/Gynecology (Women’s Health) | Family Medicine
Disease Category: Breast Cancer
Location: United States, WV
CIRB) NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
The primary aim is to determine the value of trastuzumab given during radiation therapy (RT) compared to RT alone in preventing the subsequent occurrence of ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral DCIS (IIBCR-SCR-DCIS) in women with HER2-positive DCIS resected by lumpectomy.
The primary endpoint is time from randomization to IIBCR-SCR-DCIS defined as ipsilateral invasive breast cancer, ipsilateral skin cancer recurrence, or ipsilateral DCIS. An IIBCR-SCR-DCIS event is defined as recurrent tumor in the ipsilateral breast parenchyma, skin of the ipsilateral breast or ipsilateral DCIS occurring after lumpectomy. In the determination of time to an IIBCR-SCR-DCIS, no statistical censoring will be performed with respect to any previous local, regional, distant recurrences or second primary cancers.
See www.hsc.wvu.edu/mbrcc/ctru/ for additional information
West Virginia University - Clinical Trials Research Unit
1637 Health Sciences South, PO Box 9260
Morgantown, WV 26506
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these